Skip to content

Second-line treatment: Clinton Foundation announces new price cut

Abacavir as potent as tenofovir for patients starting HIV treatment with a high viral load

Updated HIV care guidelines issued in USA

ddI treatment sole risk factor for noncirrhotic portal hypertension

Nevirapine matches atazanavir/ritonavir in 48-week study

Genotypic tests matches tropism test in predicting who benefits from CCR5 inhibitors

Raltegravir moves closer to approval for first-line use in Europe

Low bone mineral density in Botswana PrEP trial participants raises concerns

Male partner clinic attendance and HIV testing associated with better outcomes for infants born to HIV-positive mothers